You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for the information contained on the Amgen international server or site which you will be accessing. The information you are about to access may not comply with the Australian regulatory environment.
For Australian specific enquiries, please click here.
You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for, and exercises no control over the organisation, views, or information contained on the server or site which you will be accessing. The information contained might not comply with the Australian regulatory environment.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
As a pioneer in biotechnology, Amgen uses cutting edge science and tools like advanced human genetics to make biologic medicines, unravel the complexities of disease and understand the fundamentals of human biology.
This is our textbook
This is our reference library
This is our lecture hall
This is our research lab
The knowledge that will help us better understand some of the world's most
harmful diseases is filed away in our biology.
It's written in our DNA.
[Applause]
At Amgen we are both students and teachers of human biology.
Before we attack a disease, our researchers study it closely to understand its mechanisms.
[Music]
To watch the body's most subtle changes, inside and out.
We are scholars in vigilant pursuit of the vital information that may transform Lives.
Over decades Amgen has developed a deep expertise in biotechnology, mastering the complex art and science of engineering new medicines through the use of living cells.
And now with unprecedented genetic information available on a large scale and more sophisticated analytic tools, we're connecting the dots between DNA and disease, allowing us to approach the development of promising new medicines with greater understanding.
We're working to turn the tide on cancer and cardiovascular disease - the leading causes of death in the world today.
We're seeking to help more people suffering from crippling rheumatoid arthritis and we're providing critical treatments for bone disease and other serious illnesses.
At Amgen,
we observe,
we theorize,
we test,
and if we come up short, we regroup, rethink, and attack the problem again.And on those days where we hit the mark, disease suffers another blow.
Humanity takes another step forward.
Then we get back to work, searching for the answers that lie deep within us.
Amgen.
We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses such as cancer, cardiovascular disease, osteoporosis, inflammatory disorders, and many others. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.
Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen's discovery research efforts—and a major contributor to the development of Amgen's deep and broad pipeline of potential new medicines. Amgen's "biology first" approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. With the advances in human genetics, Amgen continues to shed new light on the molecular roots of disease. Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.
The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines, which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.
Established in 1991 and headquartered in Sydney, Amgen Australia works to further the company’s global efforts to transform the promise of science and biotechnology into therapies that restore health and save lives.
Hundreds of thousands of Australians use one of Amgen’s products and thousands more have been enrolled in clinical studies that have helped deliver the next generation of innovative treatments. Amgen Australia is proud to support these patients and to contribute to the development of new therapies in partnership with Australia’s leading healthcare, academic, research, government, and patient organisations.
To find out more Amgen Australia, download our fact sheet.